Cost Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors Compared with Mineralocorticoid Receptor Antagonists among Patients with Heart Failure and a Reduced Ejection Fraction
Objective: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are approved for heart failure with reduced ejection fraction (HFrEF). However, their cost-effectiveness remains unknown. We aimed to compare the cost-effectiveness of SGLT2i versus mineralocorticoid antagonists (MRAs). Methods: Data fr...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2023-05-01
|
| Series: | Cardiovascular Innovations and Applications |
| Online Access: | https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0037 |